Why the study?
Does the presence of cerebral small vessel disease increase the risk of adverse clinical outcomes in stroke patients treated with oral anticoagulation for atrial fibrillation?
Population
320 patients treated with oral anticoagulation following atrial fibrillation stroke
Design
Cohort
Follow-up
Median 754 (interquartile range 708–828) days
Key result
In stroke patients on oral anticoagulation, cerebral microbleeds increased the risk of ischemic stroke, hemorrhage, or death (OR 2.05; 95% CI 1.27-3.31; P=0.003).
Authors
Loading...
SVD was associated with unfavourable outcomes despite anticoagulation after AF stroke; leaves open whether imaging should modify secondary prevention.
Observational (n=320)
Does the presence of cerebral small vessel disease increase the risk of adverse clinical outcomes in stroke patients treated with oral anticoagulation for atrial fibrillation?
In atrial fibrillation patients on oral anticoagulation after a stroke, the presence of cerebral small vessel disease is associated with a significantly higher risk of recurrent ischemic stroke, intracranial hemorrhage, and death.
Odds Ratio: 2.05 (95% CI 1.27–3.31)
p-value: p=0.003
Hert et al. (2019) conducted an observational in Atrial fibrillation stroke (n=320). Cerebral small vessel disease (cerebral microbleeds and white matter hyperintensities) was evaluated on Composite of ischaemic stroke, intracranial haemorrhage, and death (OR 2.05, 95% CI 1.27-3.31, p=0.003). In stroke patients on oral anticoagulation, cerebral microbleeds increased the risk of ischemic stroke, hemorrhage, or death (OR 2.05; 95% CI 1.27-3.31; P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: